A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) (NCT02586857)

🧪 Interventions in This Study

• ACP-196 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

• Research Site — Los Angeles, California
• Research Site — Palo Alto, California
• Research Site — Boston, Massachusetts
• Research Site — Boston, Massachusetts
• Research Site — Boston, Massachusetts
• Research Site — New York, New York
• Research Site — Vancouver, Washington

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma Multiforme

• A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
• Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) — Baltimore, Maryland
• Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
• A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
• Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California

Explore by condition: All Glioblastoma Multiforme clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.